| Candidate Recommendation | Interpretation/Justification Comments | Ontario Context Comments | New Evidence Likely? | Assessment? (Endorse/Endorse with Changes/Reject) |
|---|---|---|---|---|
| The routine use of adjuvant chemotherapy for all patients with stage II [TYPE] cancer is not recommended. | None | None | No | Endorse |
| When treated with adjuvant therapy, high-risk stage II patients should receive [DRUG A] or [DRUG B]. | None | [DRUG A] is not yet funded in Ontario. | No | Endorse with Changes |
| Adjuvant chemotherapy with a [DRUG B] monotherapy regimen following surgery in patients who have [MARKER] is recommended. | The guideline authors overestimated the net benefit of [DRUG B] in the population for [REASONS]. | None | None | Reject |
Back to the the CCO Endorsement Protocol